Use of novel lipid mediators to inhibit angiogenesis
AssigneeThe Brigham and Women's Hospital, Inc.
InventorsCharles N. Serhan, Reza Dana, Yiping Jin
Life of this patent
Estimating the term…
Loading patent…
AssigneeThe Brigham and Women's Hospital, Inc.
InventorsCharles N. Serhan, Reza Dana, Yiping Jin
Estimating the term…
The present invention is generally drawn to novel isolated therapeutic agents, termed resolvins, generated from the interaction between a dietary omega-3 polyunsaturated fatty acid (PUFA) such as eicosapentaenoic acid (EPA) or docosahexaenoic acid (DHA) oxygenases and the analgesic aspirin (ASA). Surprisingly, careful isolation of compounds generated from the combination of components in an appropriate environment provide di- and tri-hydroxy containing derivatives of EPA or DHA containing compounds having unique structural and physiological properties. The present invention therefore provides for many new useful therapeutic di- and tri-hydroxy derivatives of EPA or DHA (resolvins of the E series and D series) that diminish, prevent, or eliminate NV, hemangiogenesis and/or angiogenic condition(s) of corneal tissue. The present invention also provides methods of use, methods of preparation, and packaged pharmaceuticals for use as medicaments for the compounds disclosed throughout the specification.
A method to treat or prevent neovascularization, comprising the step of treating corneal tissue with compound comprising the formula:
A method to treat or prevent hemangiogenesis, comprising the step of treating corneal tissue with compound comprising the formula:
A method to treat or prevent an angiogenic condition of corneal tissue, comprising the step of treating corneal tissue with compound comprising the formula:
Dependencies are inferred from the claim text.